HEME OXYGENASE AND NEONATAL HYPEROXIC INJURY
血红素加氧酶和新生儿高氧损伤
基本信息
- 批准号:6476785
- 负责人:
- 金额:$ 31.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-12-07 至 2003-07-10
- 项目状态:已结题
- 来源:
- 关键词:animal tissue antioxidants antisense nucleic acid atomic absorption spectrometry autoradiography cytoprotection densitometry enzyme activity fluorescence spectrometry fluorescent dye /probe gene expression genetically modified animals glutathione heme oxygenase hemoprotein hyperoxia isozymes laboratory mouse newborn animals oxidative stress particle counter peroxidation respiratory gas analyzer tissue /cell culture
项目摘要
Oxygen toxicity may cause deleterious effects in the lung and may
account for some of the changes of chronic lung disease of the newborn.
The inducible isoenzyme of heme oxygenase (HO-1) is known to be
upregulated in hyperoxia. Furthermore, moderate levels of HO-1
expression are associated with increased protection against oxygen
toxicity in vitro. However, the effect of higher HO-1 expression has
not been examined clearly and preliminary studies suggest an optimal
range of HO-1 over-expression in antioxidant defenses in vitro. Nothing
is known about the effect of over-expression or elimination of HO-2, the
constitutive isoenzyme in vitro, but recent observations suggest that
HO-2, unlike HO-1, may additionally serve to sequester heme at two
binding sites thereby suggesting that the two isoenzymes serve in
differing roles in oxygen toxicity. As to the in vivo role of both HO
isoenzymes, it has recently been shown that absence of HO is detrimental
to adult mutant mice. Aging null mutants lacking HO-1 had increased
markers of oxidative injury and younger HO-2 null mutants had increased
susceptibility to oxygen toxicity. Since it is known that both HO-1 and
H0-2 are expressed at higher levels in the lungs of newly born animals
compared to adults, we speculate that HO is even more relevant to
neonatal antioxidant defense in vivo. In this proposal, in order to
further define the role of HO in antioxidant defense, we plan to
precisely modulate HO expression in cultured fetal pulmonary cells using
a tetracycline regulated promoter to define whether there is an optimal
range HO expression in vitro. We will also use neonatal mutant mice
that lack HO-1 or HO-2 and transgenic mice which over-express HO-1 or
HO-2 to determine if HO expression is associated with protection against
hyperoxia in vivo. Lastly, we will determine whether differences exist
in the antioxidant function of HO-1 and HO-2 in vitro and in vivo. Prior
to considering modulation of HO as a therapeutic intervention, it will
be necessary to clarify whether HO is protective against hyperoxic
injury in vivo and to understand what manner and magnitude of HO
expression is most beneficial to cells. A better understanding of the
role of lung HO in the neonate will allow us to identify strategies to
enhance this endogenous neonatal antioxidant defense.
氧毒性可能会在肺中引起有害作用,并且可能
解释了新生儿慢性肺部疾病的某些变化。
血红素加氧酶(HO-1)的诱导同工酶已知为
在高氧中上调。 此外,HO-1的水平中等
表达与对氧气的保护增加有关
体外毒性。 但是,较高的HO-1表达的影响具有
未清楚检查,初步研究表明最佳
HO-1在体外抗氧化剂防御中的过表达范围。 没有什么
已经知道过表达或消除HO-2的影响
体外组成型同工酶,但最近的观察结果表明
HO-2与HO-1不同,可以另外用来隔离两个
结合位点,因此表明两个同工酶在
在氧毒性中的作用不同。 至于两个ho的体内角色
同工酶,最近已证明缺乏HO是有害的
到成年突变小鼠。 缺乏HO-1的衰老零突变体增加了
氧化损伤和年轻HO-2无效突变体的标记增加了
对氧毒性的敏感性。 由于知道HO-1和
H0-2在新生动物的肺中以较高的水平表示
与成年人相比,我们推测HO与
新生儿抗氧化剂防御体内。 在此提案中,为了
进一步定义了HO在抗氧化防御中的作用,我们计划
精确调节培养的胎儿肺细胞中HO表达
四环素调节的启动子,以定义是否有最佳
体外范围HO表达。 我们还将使用新生儿突变小鼠
缺乏过表达HO-1或的HO-1或HO-2和转基因小鼠
HO-2确定HO表达是否与保护有关
体内高氧。 最后,我们将确定是否存在差异
在体外和体内HO-1和HO-2的抗氧化功能中。事先的
要考虑调节HO作为治疗性干预措施,它将
有必要阐明HO是否可以保护过度氧气
体内受伤并了解HO的方式和大小
表达对细胞最有益。 更好地理解
肺Ho在新生儿中的作用将使我们能够确定策略
增强这种内源性新生儿抗氧化剂防御。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PHYLLIS A. DENNERY其他文献
PHYLLIS A. DENNERY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PHYLLIS A. DENNERY', 18)}}的其他基金
Regulation of the Lung Circadian Clock by Heme Oxygenase-1
血红素氧合酶 1 对肺生物钟的调节
- 批准号:
8795882 - 财政年份:2014
- 资助金额:
$ 31.71万 - 项目类别:
Regulation of the Lung Circadian Clock by Heme Oxygenase-1
血红素氧合酶 1 对肺生物钟的调节
- 批准号:
8445540 - 财政年份:2013
- 资助金额:
$ 31.71万 - 项目类别:
Regulation of the Lung Circadian Clock by Heme Oxygenase-1
血红素氧合酶 1 对肺生物钟的调节
- 批准号:
8620708 - 财政年份:2013
- 资助金额:
$ 31.71万 - 项目类别:
Zinc Protoporphyrin and the Cell Cycle in Neonatal Mice
锌原卟啉和新生小鼠的细胞周期
- 批准号:
7236134 - 财政年份:2004
- 资助金额:
$ 31.71万 - 项目类别:
Zinc Protoporphyrin and the Cell Cycle in Neonatal Mice
锌原卟啉和新生小鼠的细胞周期
- 批准号:
7057832 - 财政年份:2004
- 资助金额:
$ 31.71万 - 项目类别:
Zinc Protoporphyrin and the Cell Cycle in Neonatal Mice
锌原卟啉和新生小鼠的细胞周期
- 批准号:
6896782 - 财政年份:2004
- 资助金额:
$ 31.71万 - 项目类别:
Zinc Protoporphyrin and the Cell Cycle in Neonatal Mice
锌原卟啉和新生小鼠的细胞周期
- 批准号:
6725069 - 财政年份:2004
- 资助金额:
$ 31.71万 - 项目类别:
GROWTH RETARDATION AND FETAL LOSS WITH HO-1 DEFICIENCY
HO-1 缺乏导致生长迟缓和流产
- 批准号:
6163568 - 财政年份:2000
- 资助金额:
$ 31.71万 - 项目类别:
GROWTH RETARDATION AND FETAL LOSS WITH HO-1 DEFICIENCY
HO-1 缺乏导致生长迟缓和流产
- 批准号:
6387775 - 财政年份:2000
- 资助金额:
$ 31.71万 - 项目类别:
相似国自然基金
抗氧化剂/活性离子时序释放复合支架构建及其修复糖尿病骨缺损的机制研究
- 批准号:32360232
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
塑料抗氧化剂内分泌干扰转化产物的识别与环境行为研究
- 批准号:22306042
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
农用地膜抗氧化剂的土壤污染特征及其微生物效应与机制研究
- 批准号:42377223
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
自然水体轮胎抗氧化剂高毒醌类衍生物非靶向识别及生物转化机制
- 批准号:42377360
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
取代对苯二胺抗氧化剂及其醌衍生物的人体内暴露标志物研究
- 批准号:22306031
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Patient-oriented Research: Colon CA & Cancer Immunology
以患者为导向的研究:Colon CA
- 批准号:
7251986 - 财政年份:2001
- 资助金额:
$ 31.71万 - 项目类别:
Patient-oriented Research: Colon CA & Cancer Immunology
以患者为导向的研究:Colon CA
- 批准号:
7386702 - 财政年份:2001
- 资助金额:
$ 31.71万 - 项目类别: